C. Difficile Testing: How Rapid PCR Can Support Diagnosis and Hospital Infection Control

c difficile pcr testing

Diarrhoea developing during or following antibiotic treatment can present healthcare professionals with an important question.

Is the patient’s illness simply an adverse effect of treatment, or could Clostridioides difficile be responsible?

The C. Difficile bacterium can cause illness ranging from diarrhoea to severe inflammation of the colon, and antibiotic exposure is one of the major factors associated with C. difficile infection (CDI).

For laboratories, the challenge is not simply detecting the organism.

Testing needs to be performed on appropriate patients, using appropriate samples, and the result must be interpreted alongside the patient’s clinical presentation.

This distinction becomes particularly important with highly sensitive molecular techniques such as PCR.

The Bosch Vivalytic C. difficile test uses qualitative real-time PCR to detect Clostridioides difficile toxin genes tcdA and tcdB from soft or liquid stool samples, with results available in approximately 54 minutes.

What Is Clostridioides Difficile?

What Is Clostridioides Difficile?

Clostridioides difficile, commonly abbreviated to C. difficile or C. diff, is a bacterium capable of causing gastrointestinal disease.

The clinical spectrum can range from relatively mild diarrhoea to severe colitis.

Bosch notes that C. difficile has particular importance in healthcare facilities such as hospitals and nursing homes and following antibiotic treatment. The manufacturer estimates that approximately 15–20% of antibiotic-associated diarrhoeal illnesses are caused by C. difficile.

Antibiotics are relevant because they can disrupt the normal bacterial community within the intestine, and this can create conditions that allow C. difficile to proliferate.

The consequences can be particularly significant for healthcare facilities because C. difficile is not only a patient-management issue; it can also quickly become an infection-prevention and outbreak-control problem.

Why Antibiotic Use Is Relevant

Antibiotics can be essential and lifesaving medicines.

However, their use can also alter intestinal microbiota and increase susceptibility to C. difficile.

This creates an important connection between diagnostics and responsible antimicrobial use.

WHO’s Antimicrobial Resistance Diagnostic Initiative specifically places improved diagnostic capacity within the broader effort to support patient management, antimicrobial stewardship, infection prevention, outbreak investigation and AMR surveillance.

For healthcare organisations, diagnostic investment therefore should not be viewed solely as purchasing laboratory equipment.

The more important objective is developing a system in which appropriate testing provides information that healthcare professionals can actually use.

Who Should Be Tested for C. Difficile?

This is one of the most important sections of the article because C. difficile PCR testing requires careful interpretation.

A highly sensitive molecular test can detect toxigenic C. difficile even when the organism may not be responsible for a patient’s symptoms.

The CDC specifically warns that molecular assays can return positive results in asymptomatic individuals and in patients whose diarrhoea has another cause.

This creates the possibility of overdiagnosis if PCR is used indiscriminately.

Laboratories should therefore avoid thinking:

“The more patients we test, the better.”

A better principle is:

“Test the appropriate patient, using the appropriate specimen, and interpret the result within the clinical context.”

Current CDC infection-prevention guidance recommends testing appropriate unformed stool specimens and suggests considering diagnostic algorithms where inappropriate testing may otherwise be a concern.

Local and national clinical guidelines should always determine the precise testing protocol used by an individual healthcare facility.

What Role Does PCR Play in C. Difficile Testing?

What Role Does PCR Play in C. Difficile Testing?

PCR (polymerase chain reaction) allows laboratories to detect specific genetic material.

In C. difficile diagnostics, molecular assays can detect genes associated with toxin-producing organisms.

The CDC describes approved PCR assays as highly sensitive same-day tests for the presence of toxigenic C. difficile.

However, there is an important distinction:

detecting toxin-associated genes is not identical to demonstrating that active toxin production is causing the patient’s symptoms.

That is why molecular results need clinical context.

Depending on local guidelines and laboratory protocols, C. difficile diagnostic strategies may involve molecular testing, toxin testing, glutamate dehydrogenase (GDH) antigen testing, culture or combinations of methods.

The correct question is therefore not necessarily:

“Is PCR better than every other C. difficile test?”

It is:

“Where should rapid PCR sit within our laboratory’s C. difficile diagnostic algorithm?”

What Does the Vivalytic C. Difficile Test Detect?

The Vivalytic C. difficile assay detects Clostridioides difficile through the toxin genes:

tcdA
and
tcdB

These correspond to genes associated with toxins A and B.

  • Bosch specifies qualitative real-time PCR as the detection method.

That distinction is important when healthcare professionals interpret what the assay actually reports.

The assay is detecting genetic targets associated with toxigenic C. difficile. The result should therefore be considered alongside the patient’s symptoms and the healthcare organisation’s diagnostic protocol rather than being interpreted independently as proof that C. difficile is necessarily causing every episode of diarrhoea in which the target is detected.

How Does the Vivalytic C. Difficile PCR Test Work?

How Does the Vivalytic C. Difficile PCR Test Work?

According to the Bosch Vivalytic portfolio, the assay uses soft and liquid stool samples.

The required sample volume is 300 μL per test, and results are available in approximately 54 minutes.

SpecificationVivalytic C. difficile
Detectable PathogenClostridioides difficile (tcdA/tcdB)
Detection MethodQualitative real-time PCR
Sample MaterialSoft and liquid stool samples
Time-to-ResultApprox. 54 minutes
Field of ApplicationSymptomatic patients
Intended SettingProfessional and laboratory use
Sample Volume300 μL per test
Transport Medium (2 ml)eNAT® (Copan) with regular FLOQSwabs®

Bosch positions the assay around fast laboratory testing for outbreak containment and states that no further laboratory equipment is required for the test workflow.

Healthcare professionals can review the manufacturer’s information on the official Bosch Vivalytic C. difficile test page.

What Happens Inside the Vivalytic Analyser?

One advantage of an integrated molecular diagnostic platform is the automation of processes that would otherwise form separate laboratory steps.

According to Bosch, the Vivalytic analyser automates:

sample preparation → cell lysis → nucleic-acid extraction → DNA amplification → bio-analytical detection.

This is relevant when evaluating equipment for laboratories that may not already operate a conventional molecular diagnostic workflow.

The question should not simply be:

“How long does the PCR reaction take?”

Instead, laboratories should examine:

“What infrastructure and hands-on laboratory processes are required between receiving the specimen and obtaining the result?”

Bosch describes Vivalytic as requiring only a few steps from sample to result for its C. difficile assay.

For some healthcare facilities, workflow simplicity may be just as important as the approximately 54-minute turnaround time.

What Could a Result in Approximately 54 Minutes Mean in Practice?

An approximately 54-minute test does not mean every patient will receive a diagnosis within 54 minutes.

Real-world turnaround time includes:

  • sample collection,
  • transportation,
  • laboratory receipt,
  • processing,
  • result validation,
  • reporting and clinical interpretation.

Nevertheless, reducing the analytical component of that process can potentially provide useful information earlier.

Why C. Difficile Diagnostic Capacity Matters in Africa

C. difficile illustrates a wider challenge facing laboratory medicine across parts of Africa.

If diagnostic capacity is limited, clinicians may have difficulty distinguishing between different causes of diarrhoeal illness.

If surveillance is limited, health authorities may also lack reliable information about how frequently particular pathogens occur.

A recent West African systematic review is particularly revealing because researchers found evidence from only four countries and concluded that significant diagnostic and surveillance gaps remain.

This does not mean every African hospital should immediately introduce C. difficile PCR testing.

Healthcare facilities have different priorities and resources.

But hospitals with significant antibiotic use, high patient volumes, infection-control responsibilities or existing gastrointestinal diagnostic requirements may reasonably ask whether C. difficile should form part of their future molecular diagnostic capacity.

That conversation also aligns with WHO’s wider effort to strengthen bacteriology and mycology diagnostic services, particularly in resource-limited settings.

C. Difficile Is Only One Gastrointestinal Application for Vivalytic

This is where the wider Vivalytic platform becomes commercially relevant.

The Bosch portfolio includes three gastrointestinal testing options:

  • Vivalytic C. difficile
  • Vivalytic Norovirus
  • Vivalytic Noro-, Rotavirus, C. diff

The combined assay detects:

  • Norovirus genogroup I/II,
  • Rotavirus Type A and Clostridioides difficile tcdA/tcdB from soft or liquid stool samples, with results available in approximately 60 minutes.

The broader Bosch portfolio extends considerably beyond gastrointestinal disease.

Vivalytic includes assays associated with:

  • Gastrointestinal infections, including C. difficile, Norovirus and Rotavirus;
  • Sexually transmitted infections;

Healthcare professionals can explore the manufacturer’s current Vivalytic test portfolio.

This is important when calculating whether a molecular diagnostic platform makes sense financially.

Rather than asking:

“How many C. difficile tests will we perform?”

a laboratory manager might ask:

“How many molecular tests could we potentially perform across gastrointestinal, respiratory, infection-control, STI and meningitis applications using the same analyser?”

The answer could produce a very different assessment of equipment utilisation.

Questions Laboratory Managers Should Consider

Before introducing rapid C. difficile PCR testing, laboratories and healthcare organisations should consider:

  • How frequently do we investigate antibiotic-associated or unexplained diarrhoea?
  • Which patients currently qualify for C. difficile testing?
  • Are specimens processed internally or sent elsewhere?
  • What is our current sample-to-result turnaround time?
  • Which diagnostic algorithm do we currently use?
  • How would a PCR-positive result be interpreted within that algorithm?
  • Do our specimen-acceptance criteria prevent testing of inappropriate samples?
  • How quickly are positive results communicated to infection-control teams?
  • Would faster results change patient-management or infection-control workflows?
  • What molecular diagnostic infrastructure do we currently have?
  • What staff training would be required?
  • How reliably can cartridges and collection materials be supplied?
  • What technical and after-sales support is available?
  • Could the same Vivalytic analyser support our other gastrointestinal or infectious-disease testing requirements?

These questions help determine whether a molecular platform addresses a genuine diagnostic need rather than simply adding another analyser to the laboratory.

Is Your Laboratory Considering Rapid C. Difficile PCR Testing?

If your hospital, laboratory, clinic or healthcare organisation is reviewing its C. difficile testing, gastrointestinal diagnostics or wider molecular diagnostic capabilities, MediDiagAfrica can provide further information about the Bosch Vivalytic platform and Vivalytic C. difficile assay.

The discussion can begin with your existing laboratory workflow:

  • How do you currently investigate suspected C. difficile infection?
  • How long does it take to receive a result?
  • Are specimens processed within your facility or referred elsewhere?
  • Could gastrointestinal PCR form part of a broader molecular diagnostic service within your organisation?

From there, you can:

Request information about the Vivalytic C. difficile test

Request a Vivalytic demonstration

Discuss your laboratory’s molecular diagnostic requirements

Enquire about Vivalytic availability in your country

Bosch notes that not every product is available in every region, so individual test availability should be confirmed for the relevant market.

This article is intended for healthcare and laboratory professionals and provides general diagnostic and product information. It should not replace clinical guidelines, professional medical judgement, local diagnostic algorithms, infection-control protocols or applicable regulatory requirements.


Leave a Reply